0001140361-17-045018.txt : 20171205 0001140361-17-045018.hdr.sgml : 20171205 20171205125627 ACCESSION NUMBER: 0001140361-17-045018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171201 FILED AS OF DATE: 20171205 DATE AS OF CHANGE: 20171205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RAY DEBANJAN CENTRAL INDEX KEY: 0001706863 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 171239177 MAIL ADDRESS: STREET 1: C/O CYTOMX THERAPEUTICS, INC. STREET 2: 151 OYSTER POINT BLVD, SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2017-12-01 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001706863 RAY DEBANJAN C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Financial Officer Common Stock 2017-11-30 5 A 0 163 12.1465 A 12289 D Common Stock 2017-12-01 4 S 0 2500 20.58 D 9789 D 163 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. /s/ Cynthia J. Ladd, as Attorney-in-Fact for Debanjan Ray 2017-12-05